Clinical trials: Convalescence
Long-COVID
Long-term COVID and Rehabilitation
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress…
- Trial name
- NCT05373043
- Testing
- Mitoquinone
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Sepsis
Role of RNA Metabolism Alterations in Persistent Immune Dysfunction After Sepsis
This study includes adult ICU patients with sepsis (according to SEPSIS 3.0) or critically ill non-septic patients with severe non-infectious conditions at Louis Mourier Hospital.
- Trial name
- SEPSI-splice (NCT07418801)
- Where
- 2 sites in France
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bronchiectasis
Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis
Study 1 is a cross-sectional investigation. Patients with clinically stable bronchiectasis (symptoms, including cough frequency, sputum volume and purulence, within normal daily variations) will undergo baseline assessment…
- Trial name
- BISER-2 (NCT02315547)
- Testing
- Antibiotics
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Institute of Respiratory Disease
COVID-19 Infection
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms.
- Trial name
- NCT04582903
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus, Convalescence
Convalescent Plasma to Stem Coronavirus (CSSC-001)
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
- Trial name
- CSSC-001 (NCT04323800)
- Testing
- Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
- Where
- 25 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Convalescence, Healthy
Screening Study for the Department of Rehabilitation Medicine
The primary function of the Department of Rehabilitation Medicine (RMD) is to diagnose and treat patients at the NIH who have problems in locomotion, activities of daily living, occupational roles, communication, swallowing, or…
- Trial name
- NCT00023088
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)